Literature DB >> 25960228

CD26 a cancer stem cell marker and therapeutic target.

Samuel Davies1, Aline Beckenkamp1, Andréia Buffon2.   

Abstract

Cancer stem cells (CSCs) comprise a tumor subpopulation responsible for tumor maintenance, resistance to chemotherapy, recurrence and metastasis. The identification of this cell group is very important, but there is still no consensus on its characterization. Several CSC markers have been described, like CD133, CD24, CD44 and ALDH1, but more research to identify new markers to facilitate the identification of CSC in a heterogeneous tumoral mass is required. Thus, this article describes the CD26 expression as a CSC marker and the role that it plays in different types of cancer. CD26 expression correlates with some characteristics of CSCs, like the formation of spheres in vitro, formation of new tumors, and resistance to chemotherapy. CD26 is therefore suggested as an auxiliary marker for CSC in different types of cancer, and as a potential therapeutic target.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CD26; CSC marker; Cancer stem cells; Indifferentiation marker; Therapeutic target

Mesh:

Substances:

Year:  2015        PMID: 25960228     DOI: 10.1016/j.biopha.2015.02.031

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  20 in total

1.  DPP4 in anti-tumor immunity: going beyond the enzyme.

Authors:  Kei Ohnuma; Ryo Hatano; Chikao Morimoto
Journal:  Nat Immunol       Date:  2015-08       Impact factor: 25.606

Review 2.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

Review 3.  Mechanisms of tumor cell resistance to the current targeted-therapy agents.

Authors:  Gholamreza Khamisipour; Farhad Jadidi-Niaragh; Abdolreza Sotoodeh Jahromi; Keivan Zandi; Mohammad Hojjat-Farsangi
Journal:  Tumour Biol       Date:  2016-05-07

4.  Integrating Molecular Networking and Biological Assays To Target the Isolation of a Cytotoxic Cyclic Octapeptide, Samoamide A, from an American Samoan Marine Cyanobacterium.

Authors:  C Benjamin Naman; Ramandeep Rattan; Svetlana E Nikoulina; John Lee; Bailey W Miller; Nathan A Moss; Lorene Armstrong; Paul D Boudreau; Hosana M Debonsi; Frederick A Valeriote; Pieter C Dorrestein; William H Gerwick
Journal:  J Nat Prod       Date:  2017-01-05       Impact factor: 4.050

Review 5.  Diagnostic and therapeutic biomarkers in colorectal cancer: a review.

Authors:  Jéssica Vieira de Assis; Lucélia Antunes Coutinho; Ifeoluwa Temitayo Oyeyemi; Oyetunde Timothy Oyeyemi; Rafaella Fortini E Queiroz Grenfell
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 6.  DPPIV/CD26: a tumor suppressor or a marker of malignancy?

Authors:  Aline Beckenkamp; Samuel Davies; Júlia Biz Willig; Andréia Buffon
Journal:  Tumour Biol       Date:  2016-03-04

7.  Suppression of CD26 inhibits growth and metastasis of pancreatic cancer.

Authors:  Chunxiang Ye; Xiuyun Tian; Guanjun Yue; Liang Yan; Xiaoya Guan; Shan Wang; Chunyi Hao
Journal:  Tumour Biol       Date:  2016-10-07

8.  Co-Culture of Tumor Spheroids and Fibroblasts in a Collagen Matrix-Incorporated Microfluidic Chip Mimics Reciprocal Activation in Solid Tumor Microenvironment.

Authors:  Su-Yeong Jeong; Ji-Hyun Lee; Yoojin Shin; Seok Chung; Hyo-Jeong Kuh
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

9.  MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features.

Authors:  Xiaoran Li; Yali Zhong; Jie Lu; Karol Axcrona; Lars Eide; Randi G Syljuåsen; Qian Peng; Junbai Wang; Hongquan Zhang; Mariusz Adam Goscinski; Gunnar Kvalheim; Jahn M Nesland; Zhenhe Suo
Journal:  Oncotarget       Date:  2016-06-28

10.  First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.

Authors:  Eric Angevin; Nicolas Isambert; Véronique Trillet-Lenoir; Benoit You; Jérôme Alexandre; Gérard Zalcman; Philippe Vielh; Françoise Farace; Fanny Valleix; Thomas Podoll; Yu Kuramochi; Itaru Miyashita; Osamu Hosono; Nam H Dang; Kei Ohnuma; Taketo Yamada; Yutaro Kaneko; Chikao Morimoto
Journal:  Br J Cancer       Date:  2017-03-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.